PE99498A1 - Polipeptidos de fusion - Google Patents

Polipeptidos de fusion

Info

Publication number
PE99498A1
PE99498A1 PE1997000662A PE00066297A PE99498A1 PE 99498 A1 PE99498 A1 PE 99498A1 PE 1997000662 A PE1997000662 A PE 1997000662A PE 00066297 A PE00066297 A PE 00066297A PE 99498 A1 PE99498 A1 PE 99498A1
Authority
PE
Peru
Prior art keywords
hsa
iger
sec
ige
dominant form
Prior art date
Application number
PE1997000662A
Other languages
English (en)
Inventor
Philip Lake
Mary Ellen Digan
Hermann Gram
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE99498A1 publication Critical patent/PE99498A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

CARACTERIZADOS PORQUE COMPRENDEN AL MENOS UN DOMINIO DE UNION DE INMUNOGLOGULINA E (IgE) FUSIONADOS A AL MENOS UN COMPONENTE DE SEROALBUMINA HUMANA (HSA), EN DONDE: EL DOMINIO DE UNION DE IgE ES IgER (FORMA MADURA DEL pre-IgER, Val26-Leu204 DE LA SEC. 1) o pre-IgER (FORMA DOMINANTE DEL Fc�RIO (DOMINIO EXTRACELULAR DEL RECEPTOR PARA IgE, SEC. 1); EL COMPONENTE HSA ES HSA-I (FORMA DOMINANTE DE LA PROTEINA NATIVA MADURA, SEC. 2), prepro-HSA-I (FORMA DOMINANTE DE LA prepro-HSA NATIVA, Met1-Gly608 DE LA SEC. 2) o HSA-II (SECUENCIA NATIVA, Asp25-Gly608 DE LA SEC. 2); EL POLIPEPTIDO DE FUSION PREFERIDO ES EL DIMERO "IgER-L1-HSAII-L2-IgER", EN DONDE: L ES UN ENLACE PREFERENTEMENTE PEPTIDICO. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE LOS POLIPEPTIDOS DE FUSION, A LOS POLINUCLEOTIDOS INTERMEDIOS, AL VECTOR DE EXPRESION Y AL ANIMAL RECOMBINATE O TRANSGENICO NO HUMANO QUE LOS EXPRESA. ESTOS POLIPEPTIDOS PUEDEN SER UTILES EN EL TRATAMIENTO DE ALERGIAS, DE PREFERENCIA DERMATITIS ATOPICA, ASMA ATOPICA Y URTICARIA CRONICA, CON UNA VIDA EN SUERO EFECTIVA MEJORADA, EN TERAPIAS GENICAS Y EN UN ENSAYO DE DIAGNOSTICO PARA DETERMINAR EL NIVEL DE IgE O LOS ANTICUERPO PARA EL Fc�RI EN UNA MUESTRA BIOLOGICA
PE1997000662A 1996-07-26 1997-07-24 Polipeptidos de fusion PE99498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69021696A 1996-07-26 1996-07-26

Publications (1)

Publication Number Publication Date
PE99498A1 true PE99498A1 (es) 1999-01-21

Family

ID=24771594

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000662A PE99498A1 (es) 1996-07-26 1997-07-24 Polipeptidos de fusion

Country Status (28)

Country Link
EP (1) EP0917581B1 (es)
JP (1) JP3681402B2 (es)
KR (1) KR100502879B1 (es)
CN (1) CN1146664C (es)
AR (1) AR008077A1 (es)
AT (1) ATE383429T1 (es)
AU (1) AU722069B2 (es)
BR (1) BR9710605A (es)
CA (1) CA2261562C (es)
CO (1) CO4650184A1 (es)
CZ (1) CZ297634B6 (es)
DE (1) DE69738452T2 (es)
ES (1) ES2300114T3 (es)
HK (1) HK1020352A1 (es)
ID (1) ID19420A (es)
IL (2) IL128094A0 (es)
MY (1) MY120425A (es)
NO (1) NO323611B1 (es)
NZ (1) NZ333908A (es)
PE (1) PE99498A1 (es)
PL (1) PL189415B1 (es)
PT (1) PT917581E (es)
RU (1) RU2209211C2 (es)
SK (1) SK7799A3 (es)
TR (1) TR199900155T2 (es)
TW (1) TW565571B (es)
WO (1) WO1998004718A1 (es)
ZA (1) ZA976666B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501905A (ja) * 1998-01-29 2002-01-22 タノックス インコーポレイテッド ＩｇＥアンタゴニストによるアトピー性皮膚炎の治療
EP1088084B1 (en) * 1998-06-15 2006-09-13 GTC Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion protein
JP2003506074A (ja) * 1999-08-09 2003-02-18 ジェネッサンス ファーマシューティカルズ，インコーポレイティド 薬剤標的同質遺伝子：免疫グロブリンｅ受容体ｉａｌｐｈａサブユニット遺伝子における多型
DE10026998A1 (de) * 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
CZ306180B6 (cs) * 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
ES2440321T3 (es) 2009-02-27 2014-01-28 Novartis Ag Métodos para seleccionar células eucarióticas que expresan una proteína heteróloga
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
RU2506271C2 (ru) * 2011-06-22 2014-02-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД А2, СЕЛЕКТИВНО СВЯЗЫВАЮЩИЙ HSA, РЕКОМБИНАНТНАЯ ДНК pa2, КОДИРУЮЩАЯ HSA-СВЯЗЫВАЮЩУЮ ЧАСТЬ ПОЛИПЕПТИДА A2, ЕГО ПРОДУЦЕНТ - РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15-A2, СОДЕРЖАЩИЙ РЕКОМБИНАНТНУЮ ПЛАЗМИДНУЮ ДНК pQE 32-pa2, ОБЕСПЕЧИВАЮЩУЮ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A2 И ПРИМЕНЕНИЕ ПОЛИПЕПТИДА А2 ДЛЯ ДИАГНОСТИКИ МИКРОАЛЬБУМИНУРИИ И ВЫДЕЛЕНИЯ HSA ИЗ СЫВОРОТКИ КРОВИ
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
BR112017023503A2 (pt) * 2015-05-04 2018-07-31 Biosourcing Sa método, composição, e, mamífero transgênico não humano.
EP3192806A1 (en) 2016-01-13 2017-07-19 Affiris AG Alpha chain of the high-affinity ige receptor (fceria)
EP3538558A4 (en) * 2016-11-09 2020-07-15 North Carolina State University TREATMENT OF ALLERGIC DISEASES WITH A CHIMERAL PROTEIN
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
KR20210006302A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 il-10 변이체 단백질 및 그의 용도
CN111773392B (zh) * 2020-05-25 2023-04-07 河南省生物工程技术研究中心 一种人血白蛋白/寡核苷酸纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
CA2059842A1 (en) * 1991-02-11 1992-08-12 Richard A. Chizzonite Ige-receptor-antibodies

Also Published As

Publication number Publication date
NO323611B1 (no) 2007-06-18
CA2261562A1 (en) 1998-02-05
IL128094A0 (en) 1999-11-30
AU4202597A (en) 1998-02-20
NZ333908A (en) 1999-10-28
TR199900155T2 (xx) 2000-08-21
ID19420A (id) 1998-07-09
EP0917581A1 (en) 1999-05-26
EP0917581B1 (en) 2008-01-09
ES2300114T3 (es) 2008-06-01
JP2000516089A (ja) 2000-12-05
WO1998004718A1 (en) 1998-02-05
ZA976666B (en) 1999-01-25
SK7799A3 (en) 1999-07-12
TW565571B (en) 2003-12-11
AU722069B2 (en) 2000-07-20
CN1229439A (zh) 1999-09-22
AR008077A1 (es) 1999-12-09
PT917581E (pt) 2008-04-11
ATE383429T1 (de) 2008-01-15
PL331356A1 (en) 1999-07-05
RU2209211C2 (ru) 2003-07-27
MY120425A (en) 2005-10-31
NO990328D0 (no) 1999-01-25
IL128094A (en) 2006-08-20
PL189415B1 (pl) 2005-08-31
NO990328L (no) 1999-02-19
BR9710605A (pt) 1999-08-17
CN1146664C (zh) 2004-04-21
KR100502879B1 (ko) 2005-07-25
CA2261562C (en) 2011-04-05
CZ24699A3 (cs) 1999-04-14
CZ297634B6 (cs) 2007-02-21
KR20000029563A (ko) 2000-05-25
CO4650184A1 (es) 1998-09-03
JP3681402B2 (ja) 2005-08-10
DE69738452D1 (de) 2008-02-21
HK1020352A1 (en) 2000-04-14
DE69738452T2 (de) 2008-12-24

Similar Documents

Publication Publication Date Title
PE99498A1 (es) Polipeptidos de fusion
Barnes et al. The collagen-platelet interaction
Cassidy et al. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders
Volkmer et al. Neurofascin induces neurites by heterophilic interactions with axonal NrCAM while NrCAM requires F11 on the axonal surface to extend neurites.
Hoffman Allergens in bee venom: III. Identification of allergen B of bee venom as an acid phosphatase
JP4717799B2 (ja) 成長因子複合体ならびに細胞の移動および増殖の調節
DE69536123D1 (de) Fusionsprotein dass bpTK7 enthält
NO975435L (no) Modifiserte/kimeriske proteiner samt anvendelse derav
Tsubamoto et al. Expression of recombinant human zona pellucida protein 2 and its binding capacity to spermatozoa
DE69837104D1 (de) An g-protein gekoppelte rezeptoren und deren verwendungen
ATE209356T1 (de) Ein verfahren zur bestimmung von kollagenfragmenten in körperflüssigkeiten, ein testkit und mittel zur durchführung des verfahrens, und seine verwendung zur feststellung von mit dem kollagenmetabolismus assoziierten störungen
DE69841037D1 (de) Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.
Hatakenaka et al. Immunohistochemical localization of chick retinal 24 kdalton protein (visinin) in various vertebrate retinae
Creutz Isolation, characterization and localization of bovine adrenal medullary myosin
Smith et al. Interaction of arrestin with enolase1 in photoreceptors
Huang et al. Immunocytochemical demonstration of rod-opsin, S-antigen, and neuron-specific proteins in the human pineal gland
ATE346154T1 (de) G-beta-gamma regulierte phosphatidylinositil-3' kinase
KR910700459A (ko) 인슐린 의존성 진성당뇨병의 조기검진 및 치료를 위한 방법 및 조성물
ATE323764T1 (de) Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda
DE69637599D1 (de) Rezeptoren für das humane Interleukin-12
Song et al. Localization and differential interaction of R7 RGS proteins with their membrane anchors R7BP and R9AP in neurons of vertebrate retina
Jean et al. Cell membrane, but not circulating, carcinoembryonic antigen is linked to a piiosphatidylinositol-containing hydrophobic domain
Wasmeier et al. The lumenal domain of the integral membrane protein phogrin mediates targeting to secretory granules
WO1992007939A3 (en) Polypeptide with 46kd hmfg differentiation antigen binding specificity
NO986218D0 (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed